NGNE Stock Overview
A biotechnology company, develops genetic medicines for rare neurological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Neurogene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.27 |
| 52 Week High | US$53.00 |
| 52 Week Low | US$12.49 |
| Beta | 0 |
| 11 Month Change | 14.99% |
| 3 Month Change | 32.82% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 166.69% |
Recent News & Updates
Shareholder Returns
| NGNE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.2% | 2.4% | 3.0% |
| 1Y | n/a | 20.4% | 25.3% |
Return vs Industry: Insufficient data to determine how NGNE performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how NGNE performed against the US Market.
Price Volatility
| NGNE volatility | |
|---|---|
| NGNE Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NGNE has not had significant price volatility in the past 3 months.
Volatility Over Time: NGNE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 91 | Rachel McMinn | www.neurogene.com |
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC.
Neurogene Inc. Fundamentals Summary
| NGNE fundamental statistics | |
|---|---|
| Market cap | US$555.61m |
| Earnings (TTM) | US$2.36m |
| Revenue (TTM) | US$925.00k |
221.3x
P/E Ratio565.7x
P/S RatioIs NGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGNE income statement (TTM) | |
|---|---|
| Revenue | US$925.00k |
| Cost of Revenue | US$52.98m |
| Gross Profit | -US$52.05m |
| Other Expenses | -US$54.41m |
| Earnings | US$2.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | -5,627.03% |
| Net Profit Margin | 255.57% |
| Debt/Equity Ratio | 0% |
How did NGNE perform over the long term?
See historical performance and comparison